Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteArtemisis Princeps Leaf Extract is extracted from Artemisia princeps Panpanini, contains some low-molecular-weight component which stimulates the proliferation of vascular endothelial cells in vitro, and is effective for promoting the restration of injured endothelium.
More Information Supplier PageArtemitin, a significant flavonol compound existing in Laggera pterodonta (DC.) Benth., Artemisia rupestris L, etc., possesses bioactivities of antioxidative, anti-inflammatory and antiviral.
More Information Supplier PageArtemitin, a significant flavonol compound existing in Laggera pterodonta (DC.) Benth., Artemisia rupestris L, etc., possesses bioactivities of antioxidative, anti-inflammatory and antiviral.
More Information Supplier PageArtesunate is a part of the artemisinin group of agents with an IC50 of < 5 μM for small cell lung carcinoma cell line H69. It is a potential inhibitor of STAT-3 and exhibits selective cytotoxicity of cancer cells over normal cells in vitro; A potent inhibitor of EXP1.
More Information Supplier PageArtesunate is a part of the artemisinin group of agents with an IC50 of < 5 μM for small cell lung carcinoma cell line H69. It is a potential inhibitor of STAT-3 and exhibits selective cytotoxicity of cancer cells over normal cells in vitro; A potent inhibitor of EXP1.
More Information Supplier PageArticaine (Ultracaine) is a dental local anesthetic which contains an additional ester group that is metabolized by estearases in blood and tissue.
More Information Supplier PageArtichoke Extract is extracted from Cynara cardunculus var. scolymus, which has antioxidant, choleretic, hepatoprotective, bile-enhancing, and lipid-lowering effects.
More Information Supplier PageARV-766 (Luxdegalutamide) is an orally active and potent degrader of proteolysis targeting chimera (PROTAC) protein. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.
More Information Supplier PageARV-766 (Luxdegalutamide) is an orally active and potent degrader of proteolysis targeting chimera (PROTAC) protein. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.
More Information Supplier PageARV-766 (Luxdegalutamide) is an orally active and potent degrader of proteolysis targeting chimera (PROTAC) protein. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.
More Information Supplier PageARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
More Information Supplier PageARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
More Information Supplier PageARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
More Information Supplier PageARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
More Information Supplier PageARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
More Information Supplier PageARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
More Information Supplier PageARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
More Information Supplier PageARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
More Information Supplier PageARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
More Information Supplier PageARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
More Information Supplier PageARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
More Information Supplier PageAS-252424 is a novel, potent PI3Kγ inhibitor with IC50 of 30 nM in a cell-free assay with 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.
More Information Supplier PageAS-252424 is a novel, potent PI3Kγ inhibitor with IC50 of 30 nM in a cell-free assay with 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.
More Information Supplier PageAS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for PI3Kγ than PI3Kα.
More Information Supplier PageAS-605240 selectively inhibits PI3Kγ with IC50 of 8 nM, over 30-fold and 7.5-fold more selective for PI3Kγ than PI3Kδ/β and PI3Kα in cell-free assays, respectively.
More Information Supplier PageAS-8351 is a histone demethylase inhibitor that could induces reprogramming of human fetal lung fibroblasts into functional cardiomyocytes.
More Information Supplier PageAS-8351 is a histone demethylase inhibitor that could induces reprogramming of human fetal lung fibroblasts into functional cardiomyocytes.
More Information Supplier PageAS057278 (3-Methylpyrazole-5-carboxylic acid, MPC) is an inhibitor of D-amino acid oxidase (DAAO).
More Information Supplier PageAS 1269574, a small-molecule G protein-coupled receptor 119 (GPR119) agonist, has an EC50 of 2.5 μM in HEK293 cells transiently expressing human GPR119 and enhances insulin secretion in the mouse pancreatic β-cell line MIN-6 only under high-glucose (16.8 mM) conditions.
More Information Supplier PageAS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM.
More Information Supplier PageAS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM.
More Information Supplier PageAS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM.
More Information Supplier PageAS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM.
More Information Supplier PageAS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM.
More Information Supplier PageAS1842856 is a cell-permeable inhibitor that blocks the transcription activity of Foxo1 with IC50 of 33 nM. It could directly bind to the active Foxo1, but not the Ser256-phosphorylated form. AS1842856 suppresses autophagy.
More Information Supplier PageAS1842856 is a cell-permeable inhibitor that blocks the transcription activity of Foxo1 with IC50 of 33 nM. It could directly bind to the active Foxo1, but not the Ser256-phosphorylated form. AS1842856 suppresses autophagy.
More Information Supplier PageAS1842856 is a cell-permeable inhibitor that blocks the transcription activity of Foxo1 with IC50 of 33 nM. It could directly bind to the active Foxo1, but not the Ser256-phosphorylated form. AS1842856 suppresses autophagy.
More Information Supplier PageAS1842856 is a cell-permeable inhibitor that blocks the transcription activity of Foxo1 with IC50 of 33 nM. It could directly bind to the active Foxo1, but not the Ser256-phosphorylated form. AS1842856 suppresses autophagy.
More Information Supplier PageAS1842856 is a cell-permeable inhibitor that blocks the transcription activity of Foxo1 with IC50 of 33 nM. It could directly bind to the active Foxo1, but not the Ser256-phosphorylated form. AS1842856 suppresses autophagy.
More Information Supplier PageAS1949490, a competitive inhibitor of 5′-lipid phosphatase SHIP2 with IC50 values of 0.62 µM and 0.34 µM for human (Ki value is 0.44 µM) and mouse respectively, promotes protein kinase C-dependent stabilization of brain-derived neurotrophic factor mRNA in cultured cortical neurons.
More Information Supplier PageAS1949490, a competitive inhibitor of 5′-lipid phosphatase SHIP2 with IC50 values of 0.62 µM and 0.34 µM for human (Ki value is 0.44 µM) and mouse respectively, promotes protein kinase C-dependent stabilization of brain-derived neurotrophic factor mRNA in cultured cortical neurons.
More Information Supplier PageAS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells.
More Information Supplier PageAS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells.
More Information Supplier PageAS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells.
More Information Supplier PageAS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells.
More Information Supplier PageAS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells.
More Information Supplier PageAS601245 is an orally active, selective, ATP-competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50 of 150, 220, and 70 nM for three JNK human isoforms hJNK1, hJNK2, and hJNK3, respectively.
More Information Supplier PageAS601245 is an orally active, selective, ATP-competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50 of 150, 220, and 70 nM for three JNK human isoforms hJNK1, hJNK2, and hJNK3, respectively.
More Information Supplier PageAsafetida Extract is derived from factice resin of Ferula sinkiangensis K. M. Shen or Ferula fukanensis K. M. Shen, which is effective in destroying intestinal worms, treatment of parasite-induced malnutrition, swelling pain in stomach and abdomen, abdominal mass, cold, malaria, diarrhea, and prevention of measles.
More Information Supplier PageAsapiprant(S-555739) is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM, which has potential as a novel therapy for allergic airway diseases.
More Information Supplier Page
